Clinuvel Pharmaceutical Forecast, price target & analysts
Clinuvel Pharmaceutical Target price 2026 - Analyst rating & recommendation
Clinuvel Pharmaceutical Classifications & Recommendation
Clinuvel Pharmaceutical Price Target
| Target Price | A$14.72 |
| Price | A$8.37 |
| Potential |
75.85%
register free of charge
|
| Number of Estimates | 8 |
|
8 Analysts have issued a price target Clinuvel Pharmaceutical 2027 .
The average Clinuvel Pharmaceutical target price is A$14.72.
This is
75.85%
register free of charge
A$41.27
393.01%
register free of charge
A$9.62
14.88%
register free of charge
|
|
| A rating was issued by 11 analysts: 7 Analysts recommend Clinuvel Pharmaceutical to buy, 4 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Clinuvel Pharmaceutical stock has an average upside potential 2027 of
75.85%
register free of charge
|
Sales and Margin forecast 2026, 2027 to 2033
| Jun '25 |
2026 Estimates |
|
|---|---|---|
| Revenue Million A$ | 95.02 | 100.13 |
| 7.76% | 5.38% | |
| EBITDA Margin | 49.37% | 43.64% |
| 10.41% | 11.60% | |
| Net Margin | 38.07% | 36.49% |
| 5.82% | 4.14% |
9 Analysts have issued a sales forecast Clinuvel Pharmaceutical 2026 . The average Clinuvel Pharmaceutical sales estimate is
This results in the following potential growth metrics:
9 Analysts have issued an Clinuvel Pharmaceutical EBITDA forecast 2026. The average Clinuvel Pharmaceutical EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
9 Clinuvel Pharmaceutical Analysts have issued a net profit forecast 2026. The average Clinuvel Pharmaceutical net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2026, 2027 to 2033
| Jun '25 |
2026 Estimates |
|
|---|---|---|
| Earnings Per Share A$ | 0.72 | 0.73 |
| 2.86% | 1.39% | |
| P/E | 11.50 | |
| EV/Sales | 1.79 |
9 Analysts have issued a Clinuvel Pharmaceutical forecast for earnings per share. The average Clinuvel Pharmaceutical EPS is
This results in the following potential growth metrics and future valuations:
Clinuvel Pharmaceutical...
Current Clinuvel Pharmaceutical Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| BELL POTTER SECURITIES |
Locked
➜
Locked
|
Locked | Jul 13 2026 |
| JEFFERIES |
Locked
➜
Locked
|
Locked | Jun 04 2026 |
| BELL POTTER SECURITIES |
Locked
➜
Locked
|
Locked | Jun 03 2026 |
| PARMANTIER & CIE |
Locked
➜
Locked
|
Locked | May 26 2026 |
| BELL POTTER SECURITIES |
Locked
➜
Locked
|
Locked | Apr 01 2026 |
| BELL POTTER SECURITIES |
Locked
➜
Locked
|
Locked | Mar 03 2026 |
| JEFFERIES |
Locked
➜
Locked
|
Locked | Mar 02 2026 |
| Analyst Rating | Date |
|---|---|
|
Locked
BELL POTTER SECURITIES:
Locked
➜
Locked
|
Jul 13 2026 |
|
Locked
JEFFERIES:
Locked
➜
Locked
|
Jun 04 2026 |
|
Locked
BELL POTTER SECURITIES:
Locked
➜
Locked
|
Jun 03 2026 |
|
Locked
PARMANTIER & CIE:
Locked
➜
Locked
|
May 26 2026 |
|
Locked
BELL POTTER SECURITIES:
Locked
➜
Locked
|
Apr 01 2026 |
|
Locked
BELL POTTER SECURITIES:
Locked
➜
Locked
|
Mar 03 2026 |
|
Locked
JEFFERIES:
Locked
➜
Locked
|
Mar 02 2026 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
